Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Is your nose fueling infected eczema and scabies sores?

NCT ID NCT07813611

Knowledge-focused Sponsor: Istanbul Medeniyet University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

Researchers are studying where the bacteria that infect skin sores come from in people with scabies or atopic dermatitis. They will compare bacteria grown from infected skin lesions with bacteria from nasal swabs to see if the same species appear in both places. A group of healthy volunteers provides nasal swabs for comparison. Participants are checked on days 7 and 14 to track how their skin responds.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the nose turns out to be a common source of the bacteria that infect eczema and scabies sores, doctors could target nasal bacteria to prevent these painful skin infections.
What could go wrong
This is a small observational study of 51 people at one center, so its patterns may not hold for other populations. It cannot prove that nasal bacteria cause skin infections, only whether the two are linked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 51 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants presenting to a dermatology clinic will include patients with dermatologist-confirmed scabies or atopic dermatitis and active impetiginized skin lesions, as well as healthy controls without inflammatory skin disease or signs of infection.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scabies group: dermatologist-confirmed scabies and an active impetiginized skin lesion. * Atopic dermatitis group: dermatologist-confirmed atopic dermatitis and an active impetiginized skin lesion. * Healthy control group: no inflammatory skin disease or clinical signs of infection. * Written informed consent (and appropriate parent/guardian permission when applicable). Exclusion Criteria: * Systemic or topical antibiotic use within the previous 14 days. * Active nasal infection or nasal symptoms. * History of nasal surgery or anatomic nasal deformity. TEST DRAFT NOTE: The source protocol contains wording that may conflict with inclusion of healthy controls; the final eligibility text must be reconciled with the ethics-approved protocol before release.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema impetigo scabies skin disease caused by bacterial infection staphylococcal infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Atopic dermatitis (AD) Impetigo Scabies Secondary bacterial skin infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Test Study Site - Replace

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.